Systemic chemotherapy is indicated in progressive or bulky advanced pancreatic neuroendocrine tumors (NETs) and in grade 3 (G3) neuroendocrine neoplasms (NENs) as per ENETS guidelines. Chemotherapy may be considered in NETs of other sites (lung, thymus, stomach, colon, and rectum) under certain conditions (e.g., when Ki-67 is at a high level [upper G2 range], in rapidly progressive disease and/or after failure of other therapies, or if somatostatin receptor imaging is negative). An ENETS Consensus Conference was held in Antibes (2015) to elaborate guidelines on the standards of care of different diagnostic procedures and therapeutic interventions in NENs. This article provides guidance on chemotherapy including therapeutic indications, dosing schedules, adverse events (including prevention and management), drug interactions, and evaluation of treatment effect for the chemotherapy agents most commonly used in NENs (streptozocin, dacarbazine, fluoropyrimidines, platinum compounds, etoposide, and irinotecan).

Additional Metadata
Keywords Chemotherapy, Dosing schedules, Drug interactions, Neuroendocrine tumors, Standard of care, Toxicity
Persistent URL dx.doi.org/10.1159/000473892, hdl.handle.net/1765/108145
Journal Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships
Citation
Garcia-Carbonero, R. (Rocio), Rinke, A. (Anja), Valle, J.W. (Juan W.), Fazio, N. (Nicola), Caplin, M, Gorbounova, V. (Vera), … Pavel, M. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy-Chemotherapy. In Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships (Vol. 105, pp. 281–294). doi:10.1159/000473892